Taysha Gene Therapies, Inc. Interest Expense
Taysha Gene Therapies, Inc. (TSHA) reported Interest Expense of $27.00 thousand for the 3-month period ending 2024-06-30, per its 10-Q filed 2024-08-12.
Discontinued › Expense Statement
us-gaap:InterestExpense · last filed 2024-08-12
- Taysha Gene Therapies, Inc. interest expense for the quarter ending 2024-06-30 was $27.00K, a 98.13% decline year-over-year.
- Taysha Gene Therapies, Inc. interest expense for the quarter ending 2024-03-31 was $29.00K, a 97.89% decline year-over-year.
- Taysha Gene Therapies, Inc. interest expense for the quarter ending 2023-12-31 was $713.00K, a 45.36% decline year-over-year.
- Taysha Gene Therapies, Inc. interest expense for the quarter ending 2023-09-30 was $1.47M, a 36.46% increase year-over-year.
- Taysha Gene Therapies, Inc. interest expense for fiscal 2023 was $5.00M, a 31.60% increase from fiscal 2022.
- Taysha Gene Therapies, Inc. interest expense for fiscal 2022 was $3.80M, a 165.97% increase from fiscal 2021.
- Taysha Gene Therapies, Inc. interest expense for fiscal 2021 was $1.43M, a 5000.00% increase from fiscal 2020.
- Taysha Gene Therapies, Inc. interest expense for fiscal 2020 was $28.00K.
| Period end | Interest Expense 3 month | Interest Expense 3 month as first filed | Interest Expense 6 month | Interest Expense 6 month as first filed | Interest Expense 9 month | Interest Expense 9 month as first filed | Interest Expense 12 month |
|---|---|---|---|---|---|---|---|
| 2024-06-30 | $27.00K 10-Q · filed 2024-08-12 | $56.00K 10-Q · filed 2024-08-12 | $769.00K derived: sum of 3 quarters · filed 2024-08-12 | $2.24M derived: sum of 4 quarters · filed 2024-08-12 | |||
| 2024-03-31 | $29.00K 10-Q · filed 2024-05-14 | $742.00K derived: sum of 2 quarters · filed 2024-05-14 | $2.21M derived: sum of 3 quarters · filed 2024-05-14 | $3.65M derived: sum of 4 quarters · filed 2024-08-12 | |||
| 2023-12-31 | $713.00K derived: 10-K 12 month − 10-Q 9 month · filed 2024-03-19 | $2.18M derived: sum of 2 quarters · filed 2024-03-19 | $3.62M derived: sum of 3 quarters · filed 2024-08-12 | $5.00M 10-K · filed 2024-03-19 | |||
| 2023-09-30 | $1.47M 10-Q · filed 2023-11-14 | $2.91M derived: sum of 2 quarters · filed 2024-08-12 | $4.29M 10-Q · filed 2023-11-14 | $5.59M derived: sum of 4 quarters · filed 2024-08-12 | |||
| 2023-06-30 | $1.44M 10-Q · filed 2024-08-12 | $2.81M 10-Q · filed 2024-08-12 | $4.12M derived: sum of 3 quarters · filed 2024-08-12 | $5.20M derived: sum of 4 quarters · filed 2024-08-12 | |||
| 2023-03-31 | $1.37M 10-Q · filed 2024-05-14 | $2.68M derived: sum of 2 quarters · filed 2024-05-14 | $3.76M derived: sum of 3 quarters · filed 2024-05-14 | $4.50M derived: sum of 4 quarters · filed 2024-05-14 | |||
| 2022-12-31 | $1.30M derived: 10-K 12 month − 10-Q 9 month · filed 2024-03-19 | $2.38M derived: sum of 2 quarters · filed 2024-03-19 | $3.13M derived: sum of 3 quarters · filed 2024-03-19 | $3.80M 10-K · filed 2024-03-19 | |||
| 2022-09-30 | $1.08M 10-Q · filed 2023-11-14 | $1.24M 10-Q · filed 2022-11-08 | $1.82M derived: sum of 2 quarters · filed 2023-11-14 | $2.49M 10-Q · filed 2023-11-14 | $3.00M 10-Q · filed 2022-11-08 | $3.18M derived: sum of 4 quarters · filed 2023-11-14 | |
| 2022-06-30 | $743.00K 10-Q · filed 2023-08-14 | $912.00K 10-Q · filed 2022-08-11 | $1.42M 10-Q · filed 2023-08-14 | $1.76M 10-Q · filed 2022-08-11 | $2.11M derived: sum of 3 quarters · filed 2023-08-14 | $2.65M derived: sum of 4 quarters · filed 2023-08-14 | |
| 2022-03-31 | $672.00K 10-Q · filed 2023-05-11 | $849.00K 10-Q · filed 2022-05-16 | $1.36M derived: sum of 2 quarters · filed 2023-05-11 | $1.91M derived: sum of 3 quarters · filed 2023-05-11 | $2.10M derived: sum of 4 quarters · filed 2023-05-11 | ||
| 2021-12-31 | $691.00K derived: 10-K 12 month − 10-Q 9 month · filed 2023-03-28 | $1.23M derived: sum of 2 quarters · filed 2023-03-28 | $1.43M derived: sum of 3 quarters · filed 2023-03-28 | $1.43M 10-K · filed 2023-03-28 | |||
| 2021-09-30 | $543.00K 10-Q · filed 2022-11-08 | $737.00K derived: sum of 2 quarters · filed 2022-11-08 | $737.00K 10-Q · filed 2022-11-08 | ||||
| 2021-06-30 | $194.00K 10-Q · filed 2022-08-11 | $194.00K 10-Q · filed 2022-08-11 | |||||
| 2020-12-31 | $0.00 derived: 10-K 12 month − 10-Q 9 month · filed 2022-03-31 | $1.00K derived: sum of 2 quarters · filed 2022-03-31 | $1.00K derived: sum of 3 quarters · filed 2022-03-31 | $28.00K 10-K · filed 2022-03-31 | |||
| 2020-09-30 | $1.00K 10-Q · filed 2021-11-10 | $1.00K derived: sum of 2 quarters · filed 2021-11-10 | $28.00K 10-Q · filed 2021-11-10 | ||||
| 2020-06-30 | $0.00 derived: 10-Q 6 month − 10-Q 3 month · filed 2021-08-16 | $27.00K 10-Q · filed 2021-08-16 | |||||
| 2020-03-31 | $27.00K 10-Q · filed 2021-05-11 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Immunocore Holdings plc (IMCR) | $1.613B | -90.43 | |
| Inhibrx Biosciences, Inc. (INBX) | United States | $1.477B | -10.08 |
| Maze Therapeutics, Inc. (MAZE) | United States | $1.457B | -12.40 |
| Hemab Therapeutics Holdings, Inc. (COAG) | United States | $1.672B | |
| NOVAVAX INC (NVAX) | United States | $1.748B | -6.26 |
| Vir Biotechnology, Inc. (VIR) | United States | $1.814B | -6.85 |
| Replimune Group, Inc. (REPL) | United States | $1.186B | -3.13 |
| Vericel Corp (VCEL) | United States | $2.011B | 93.97 |
| Vor Biopharma Inc. (VOR) | United States | $1.091B | 1.60 |
| MeiraGTx Holdings plc (MGTX) | United States | $1.061B | 16.10 |